[PDF][PDF] FOLFOX plus cetuximab in first-line therapy of advanced colorectal cancer
R Ehrenberg, N Halama - Annals of Translational Medicine, 2018 - cdn.amegroups.cn
Oxaliplatinum is derivate of platinum, which has been used for colorectal cancer since 1997
in France for first-line therapy of metastatic colorectal cancer. Following the data from the …
in France for first-line therapy of metastatic colorectal cancer. Following the data from the …
[HTML][HTML] FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
C Bokemeyer, CH Köhne, F Ciardiello, HJ Lenz… - European journal of …, 2015 - Elsevier
Background The OPUS study demonstrated that addition of cetuximab to 5-fluorouracil,
folinic acid and oxaliplatin (FOLFOX4) significantly improved objective response and …
folinic acid and oxaliplatin (FOLFOX4) significantly improved objective response and …
169P First-line FOLFOX-4 6 cetuximab in patients with RAS wild-type metastatic colorectal cancer: The open-label, randomized, phase 3 TAILOR trial
S Qin, J Xu, L Wang, Y Cheng, T Liu… - Annals of …, 2016 - annalsofoncology.org
Background Cetuximab in combination with chemotherapy (FOLFIRI or FOLFOX) is a
standard-of-care first-line treatment for patients (pts) with RAS wild-type (wt) metastatic …
standard-of-care first-line treatment for patients (pts) with RAS wild-type (wt) metastatic …
Biweekly cetuximab plus FOLFOX6 as first-line therapy in patients with RAS wild-type metastatic colorectal cancer: the CEBIFOX trial
S Kasper, J Meiler, H Knipp, T Höhler, P Reimer… - Clinical Colorectal …, 2020 - Elsevier
Background The multicenter, single-arm, phase II study CEBIFOX evaluated the efficacy of a
biweekly cetuximab administration in combination with FOLFOX6 as first-line therapy in …
biweekly cetuximab administration in combination with FOLFOX6 as first-line therapy in …
Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without …
C Bokemeyer, CH Kohne, F Ciardiello, HJ Lenz… - 2014 - ascopubs.org
3505 Background: The addition of cetuximab to FOLFOX4 significantly improved
progression-free survival and response in the first-line treatment of patients (pts) with KRAS …
progression-free survival and response in the first-line treatment of patients (pts) with KRAS …
Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 …
AL Cheng, GH Cornelio, L Shen, TJ Price, TS Yang… - 2015 - ascopubs.org
566 Background: The Asia-Pacific, multicenter, nonrandomized, phase II APEC study
previously reported that first-line therapy for pts with KRAS ex 2 wt mCRC consisting of C …
previously reported that first-line therapy for pts with KRAS ex 2 wt mCRC consisting of C …
Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results …
F Ciardiello, HJ Lenz, CH Kohne, V Heinemann… - 2014 - ascopubs.org
LBA443 Background: The phase III CRYSTAL study showed patients with unresectable
KRAS exon 2, codon 12 and 13, wild-type (wt) mCRC (n= 666) to benefit from the addition of …
KRAS exon 2, codon 12 and 13, wild-type (wt) mCRC (n= 666) to benefit from the addition of …
KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
C Bokemeyer, I Bondarenko, JT Hartmann… - Journal of Clinical …, 2008 - ascopubs.org
4000 Background: Efficacy analyses of the randomized phase II OPUS trial have previously
failed to show significant improvements in progression-free survival time (PFS) or overall …
failed to show significant improvements in progression-free survival time (PFS) or overall …
Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the …
S Qin, W Guo, JM Xu, Q Li, Y Cheng, TS Liu, J Chen… - 2018 - ascopubs.org
3521 Background: The survival advantage conferred by the addition of cet to FOLFOX
chemotherapy was verified in TAILOR, the first prospective, randomized, phase 3 study of …
chemotherapy was verified in TAILOR, the first prospective, randomized, phase 3 study of …
FOLFOX4 plus cetuximab for patients with previously untreated metastatic colorectal cancer according to tumor RAS and BRAF mutation status: updated analysis of …
K Kaczirek, TE Ciuleanu, D Vrbanec, E Marton… - Clinical colorectal …, 2015 - Elsevier
Background This updated analysis of the CECOG/CORE 1.2. 002 study investigated the
association between clinical outcome and RAS and BRAF mutations in metastatic colorectal …
association between clinical outcome and RAS and BRAF mutations in metastatic colorectal …